YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided unaudited earnings guidance for the year ended December 31, 2022. For the period, the Group is expected to record net profit attributable to the parent company of approximately RMB 68 million as compared to the net loss attributable to the parent company of approximately RMB 588 million for the year ended 31 December 2021.